Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

BACKGROUND: Abemaciclib demonstrated efficacy in hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their management, and whether AEs or dose reductions influenced progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, Hope S., Huober, Jens, García‐Sáenz, José A., Masuda, Norikazu, Sohn, Joo Hyuk, Andre, Valerie A.M., Barriga, Susana, Cox, Joanne, Goetz, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794176/
https://www.ncbi.nlm.nih.gov/pubmed/32955138
http://dx.doi.org/10.1002/onco.13531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794176/
https://www.ncbi.nlm.nih.gov/pubmed/32955138
http://dx.doi.org/10.1002/onco.13531

Ejemplares similares